- Advanced medical and research infrastructure
- Government rebate of up to 43.5% on clinical trial spend
- Simple and fast regulatory pathways
Australia is a developed nation with the world's top five per capita income and the second-highest human development index globally. It performs strongly in international comparisons of quality of life, health, education, and other measures.
More than one-quarter of Australians are born overseas, and more than 10% of Australians have Asian heritage.
Australia is home to some of the world’s best medical researchers and health professionals and enjoys world-class research infrastructure equal to the US. Clinical trial capability is also of an international standard and the country is well suited to conduct complex trials that are generally focused on indications aligned with the standard of care in developed nations.
With streamlined regulatory requirements and the supportive R&D Government refund of up to 43.5% on clinical research spend, Australia has become a preferred destination for early phase clinical trials.
Importantly Australia also offers alternative recruitment potential to northern hemisphere seasonally related studies.
Recently the activity growth of biotechnology companies in Australia grew about +18%, with oncology, neurology and infectious diseases representing about half of the clinical activity.
Novotech has built strong expertise over the years in providing CRO services to biotechnology companies in Australia.
In Australia, biotechnology companies enjoy start-up timelines of around 6 to 8 weeks, from Ethics Committee (EC) submission to Therapeutic Goods Administration (TGA) approval. Furthermore, Australia has 5 of the top 50 global medical schools and is one of the leading contributors in life sciences research as measured by the H-Index.